Drugs / PDNO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05699486 | Oct 2022 → Dec 2023 | pulmonary hypertension | Attgeno AB | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDNO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05699486 ↗ |
| Route | Intravenous | “intravenous PDNO infusion” NCT05699486 ↗ |